



Preliminary phytochemical and anticonvulsant studies on the root extracts of *Ficus capensis* Thunb. (Moraceae)

Abdulrazaq Sanusi^{1,2*}, Halimatu S. Hassan², Yahaya M. Sani², Aliyu M. Musa², Umar U. Pateh², Mohamed G. Magaji³, Maryam A. Mahmoud², Amina J. Yusuf⁴ and Maria M. Mailafiya⁵

¹Department of Pharmaceutical and Medicinal Chemistry, Bauchi State University, Gadau, Bauchi State, Nigeria.

²Department of Pharmaceutical and Medicinal Chemistry; ³Department of Pharmacological and Therapeutics, Ahmadu Bello University, Zaria, Nigeria.

⁴Department of Pharmaceutical and Medicinal Chemistry, Usmanu Danfodiyo University, Sokoto, Nigeria.

⁵Department of Pharmaceutical and Medicinal Chemistry, Gombe State University, Gombe, Nigeria.

Received 26th October 2017; Accepted 10th January 2018

Abstract

Ficus capensis Thunb. (Moraceae) is used in West Africa to manage different ailments including epilepsy, leprosy, neuralgia, weakness, stiffness, oedema, amenorrhoea and difficult childbirth. The aim of the study was to carry out preliminary phytochemical screening, acute toxicity and anti-convulsant studies of the methanol root extract (MRE) and hexane fraction of *Ficus capensis*. The preliminary phytochemical screening of the MRE and its fractions were carried out using standard procedures. Anticonvulsant activity was studied using Maximum electro-shock induced seizure test (MEST) in chicks and Pentylenetetrazole (PTZ)-induced seizure in mice. Preliminary phytochemical screening of the MRE and its fractions revealed the presence of various secondary metabolites. The intraperitoneal median lethal doses of MRE and WHF in mice were found to be 1,131 and 1,264 mg/kg respectively. No protection was recorded for MRE and WHF against maximal electro-shock induced convulsion; the standard drug, Phenytoin (20 mg/kg) had 100 % protection. The MRE (300 mg/kg) and WHF (100, 200 and 400 mg/kg) produced a significant ($P < 0.05$, $P < 0.001$) dose independent anticonvulsant activity in the PTZ-induced seizure in mice; the standard drug, sodium valproate (200 mg/kg) had 100 % protection. The finding of the study suggests that the root extracts of *Ficus capensis* possess significant anticonvulsant activity validating the ethno-medicinal use of the plant in management of epilepsy.

Keywords: *Ficus capensis*; Phytochemical screening; Acute toxicity study; Anticonvulsant studies

INTRODUCTION

Epilepsy is a chronic neurologic disorder of periodic and unpredictable seizures (provoked and unprovoked) which results from abnormal electrical activity in the brain [1,2]. Epilepsy could also be due to abnormal recurrent and spontaneous electrical discharge of a group of neurons in the brain

and exhibits itself as a seizure occurrence in the patients [3]. Epilepsy is one of the most prevalent neurological disorders with about 0.5 to 1% of world population [4,5]. Medicinal plants are those plants that are used in treating and preventing specific ailments and diseases that affect human beings [6]. Medicinal plants have many biological

* Corresponding author. E-mail: abdulrazaqsanusi84@gmail.com Tel: +234 (0) 8133999992

activities such as anti-neoplastic, anticonvulsant, antiviral, anti-inflammatory, anti-pyretic, analgesic and anti-malarial [7]. Several hundreds of plants are good sources of medicinal plants that are used in traditional medicine for many different purposes [8]. Traditional plants are used for the treatment of diseases in different parts of the world [9]. About 80% (3.5 to 4 billion) of people in developing countries depend on plants as source of drugs [10]. Herbal remedies used in traditional folk medicine provide an interesting and still largely unexplored source for the development of potentially new drugs for the treatment of diseases [11]. Medicinal plants are known to contain some bioactive secondary metabolites (compounds) such as tannins, alkaloids, flavonoids, carbohydrates, terpenoids and steroids which produce definite physiological action on human body [12,13].

The plant, *Ficus capensis* belongs to the family Moraceae, a large family of about 40 genera and over 1000 species [14]. The plant is also known as *Ficus sur* (Forssk) [15]. *Ficus capensis* is distributed in North-Eastern and Western Nigeria as well as tropical Africa and Islands [14]. The English name is *fig cape*. It is commonly called *Opoto*, in Yoruba, *Girka* (Shira), *Haguguwa* (Hadaija), *Farin baure* (Zaria) in Hausa, *Okwe* in Igbo [14]. The plant is *Rima bichehi* in Fulani and *Obada* in Edo language [16,17]. The plant *Ficus capensis* is a deciduous tree with spreading roots and branches and broad green leaves [18]. *Ficus capensis* is a sacred tree with medico-magic and magico-religion uses. The root of *Ficus capensis* is used in treatment of cancer. The root is also use for the treatment of epilepsy, leprosy, neuralgia, weakness, stiffness, edema, amenorrhea and difficult childbirth [14].

Ficus capensis has been reported to have antimicrobial activity [18,19]. *Ficus capensis* have also been reported to have effect on gastrointestinal motility properties

[17]. The leaves and stem bark of *Ficus capensis* have been reported to have antibacterial activity [20]. The leave has also been reported to be useful in controlling diarrhea [17]. *F. capensis* leaves extract have been reported to have clinical relevance in the management of anemia and immunity-dependent disorders [21]. *F. capensis* leaves extract at a very low concentration have been reported to favour spermatogenesis, thus demonstrating a potential to treat azoospermia [22]. Antiabortifacient [23], immune-stimulatory [24], antidiarrhoea [25], antioxidant [26], pro-fertility in treating azoospermia [27] and anti-sickling effect of red blood cells [28]. Leaves of *F. capensis* have been a potential source of natural antioxidant, antimicrobial and anti-inflammatory drugs [29]. Epilepsy is a neurological disorder, which could be as a result of damage, injury, chemical or metabolic assault [30]. About 50 million people in the world have epilepsy [31] out of which one-third of them are not being adequately managed with the currently available antiepileptic drugs because of non-compliance as a result of long-term therapy, unwanted side effects, high cost and even unavailability of the drugs [1]. Epilepsy (also known as the falling sickness) is one of the most prevalent neurological disorders in many communities in Nigeria [32]. We report herein the preliminary phytochemical screening, acute toxicity and anti-convulsant studies of the methanol root extract and hexane fraction of *Ficus capensis*.

EXPERIMENTAL

Collection, identification and preparation of plant material. The root of *Ficus capensis* was collected in July 2016 at Sakaru village, Zaria Local Government Area of Kaduna State. It was identified by U.S. Gallah at the point of collection and further authenticated by Namadi Sanusi at the Herbarium unit, Department of Biological Sciences, Ahmadu

Bello University, Zaria by comparing with herbarium reference voucher specimen (No. 900153). The root was shade dried, size reduced to powder, labelled and stored at room temperature for use.

Extraction procedures. The powdered root (4.162 g) was extracted with 70% methanol (20 L) using cold maceration method for 10 days. The extract was evaporated *in-vacuo* using rotary evaporator to yield a dark-brown residue (396 g) subsequently referred to as the methanol root extract (MRE). MRE (250 g) was suspended in distilled water and filtered. The water insoluble portion of the methanol root extract was partitioned successively with n-hexane (3.5 L), chloroform (2 L), ethylacetate (2.5 L) and n-butanol (2.5 L) to obtain water insoluble hexane fraction (WHF), water insoluble chloroform fraction (WCF), water insoluble ethylacetate fraction (WEF), water insoluble n-butanol fraction (WBF) and the water insoluble residual fraction (WF) respectively. The extract and fractions were subjected to thin-layer chromatography using different solvent systems.

Preliminary phytochemical screening.

Different chemical tests were carried out on the Methanol Root Extract (MRE), hexane (WHF), chloroform (WCF), ethylacetate (WEF) and n-butanol fractions (WBF) to identify the presence of various phytochemical constituents using standard operating procedure.

Acute toxicity studies. The method described by Lorke [33] was employed. The route of administration was intra-peritoneal. In the first phase, nine mice of either sex were divided into three groups containing three mice each. The first, second and third groups received 10, 100 and 1000 mg/kg of extract respectively. In the second phase, four animals were used. Each of the four animals received different doses of the extract, which are: 200, 400, 800 and 1600 mg/kg as a result

of the outcome of phase I study. The median lethal dose was calculated using the following formula

$$LD_{50} = \sqrt{\text{Minimal lethal dose} \times \text{Maximal survival dose}}$$

The hexane fraction was similarly studied.

Maximum electro-shock induced seizure test in chicks.

The method described by Swinyard & Kupferberg [34] was employed in this study. The anticonvulsant study of MRE involves fifty chicks divided into five groups (n=10). Group 1 (Negative control) received normal saline intraperitoneally (i.p). Groups 2, 3 and 4 (treatment groups) received graded doses of the methanol root extract 75, 150 and 300 mg/kg respectively. Group 5 (positive control) received 20 mg/kg of Phenytoin. The route of administration was intraperitoneal. The animals were observed for 30 minutes after which they were subjected to maximum electro-shock induced seizure in all the groups. The lack of tonic extension of the hind limb and an episode of HLTE was regarded as protection and full convulsion respectively. In unprotected animals, the recovery time was recorded. UGO Basile electroconvulsive unit ECT 800 fitted with ear clip electrode with shock duration of 0.8 sec, current 80 mA, pulse width 0.6 ms and frequency pulse of 100 Hz was used. The hexane fraction was similarly treated as above with doses of 100, 200 and 400 mg/kg.

Pentylentetrazole (PTZ) induced seizure in mice.

The method described by Swinyard & Kupferberg [34] was also employed in this protocol. Thirty mice were divided into five groups (n=6). Group 1 (Negative control) received normal saline intraperitoneally (*i.p.*). Groups 2, 3 and 4 (treatment groups) received graded doses of the methanol root extract 75, 150 and 300 mg/kg respectively. Group 5 (positive control) received 200 mg/kg of sodium valproate. The route of administration was intraperitoneally. After thirty minutes, all the groups were administered 20 mg/kg of the

freshly prepared PTZ subcutaneously. All the mice were observed for a period of thirty minutes after the sc. PTZ administration for the onset of HLTE and death, which were recorded for statistical analysis. The hexane fraction was similarly treated with the doses of 100, 200 and 400 mg/kg.

Statistical analysis. Data were presented as Mean \pm SEM as well as percentages. Data were analyzed using one-way Analysis of Variance (ANOVA) followed by post hoc Dunnett test for multiple comparisons. Differences were considered significant at $p < 0.05$.

RESULTS

Preliminary phytochemical screening conducted on the methanol root extract (MRE) of *F. capensis* revealed the presence of carbohydrates, glycosides, steroids,

triterpenes, tannins, flavonoids, alkaloids and saponins. WEF and WBF contain similar constituents as MRE except steroids and triterpenes. WHF revealed the presence of steroids, triterpenes and tannins while WCF indicated the presence of steroids, triterpenes, alkaloids, flavonoids and saponins (Table 1). The MRE (75, 150 and 300 mg/kg) and WHF (100, 200 and 400 mg/kg) did not protect the chicks in MEST model. Phenytoin, the standard drug gave maximum (100 %) protection to chicks (Table 2 and 3) respectively. There was a significant ($P < 0.05$, $P < 0.001$) dose independent anticonvulsant activity in the PTZ-induced seizure in mice. MRE at 300 mg/kg had 33.3 % protection to mice against seizure while WHF exhibited 33.3, 50 and 33.3 % protection at 100, 200 and 300 mg/kg (Table 4 and 5) respectively.

Table 1: Phytochemical screening of the MRE, WHF, WCF, WEF and WBF

Constituent	Test	MRE	WHF	WCF	WEF	WBF
Carbohydrates	Molisch	+	-	-	+	+
	Fehling's	+	-	-	+	+
Anthraquinones	Bontrager	-	-	-	-	-
Glycosides	Keller-Killiani	+	-	-	+	+
Steroids/Terpenes	Liebermann-Burchard	+	+	+	-	-
	Salkowski	+	+	+	-	-
Tannins	Lead acetate	+	+	-	+	+
Flavonoids	Sodium hydroxide	+	-	+	+	+
	Shinoda	+	-	+	+	+
	Ferric chloride	+	-	+	+	+
Alkaloids	Dragendorff	+	-	+	+	+
	Mayer	+	-	-	+	+
	Wagner	+	-	+	+	+
Saponin	Frothing	+	-	+	+	+

+ = present, - = absent MRE = methanol root extract, WHF = Water insoluble hexane fraction, WCF = Water insoluble chloroform fraction, WEF = Water insoluble ethyl acetate fraction, WBF = Water insoluble butanol fraction.

Table 2: Effect of MRE and PHT on maximal electro shock induced seizure in chick

Treatment (mg/kg)	Mean recovery seizure (min)	Quantal protection	Protection against seizure (%)
NS	8.33 \pm 0.69	0/10	0.0
MRE 75	7.50 \pm 1.66	0/10	0.0
MRE 150	14.83 \pm 0.83	0/10	0.0
MRE 300	16.17 \pm 0.72	0/10	0.0
PHT 20	-	10/10	100.0

Values are presented as Mean \pm SEM, One way ANOVA followed by Dunnett's Post hoc test, n=10, NS = Normal saline, MRE = Methanol Root Extract of *Ficus capensis*, PHT = Phenytoin

Table 3: Effect WHF and PHT on maximal electro shock induced seizure in chick

Treatment (mg/kg)	Mean recovery seizure (min)	Quantal protection	Protection against seizure (%)
NS	8.33±0.69	0/10	0.0
WHF 100	9.83±2.53	0/10	0.0
WHF 200	10.33±2.44	0/10	0.0
WHF 400	6.67±0.90	0/10	0.0
PHT 20	-	10/10	100.0

Values are presented as Mean ± SEM, One way ANOVA followed by Dunnett's Post hoc test, n=10, NS = Normal saline, WHF = Hexane fraction of *Ficus capensis*, PHT = Phenytoin

Table 4: Effect MRE and SV on pentylenetetrazole induced seizure in mice

Treatment (mg/kg)	Mean onset of seizure (min)	Quantal protection	Protection against seizure (%)
NS	9.17±1.55	0/6	0.0
MRE 75	16.00±4.06	2/6	33.3
MRE 150	17.83±3.54	2/6	33.3
MRE 300	21.00±2.62*	2/6	33.3
SV 200	-	6/6	100.0

Protection against seizure and mortality expressed as percentages; Mean onset of seizures presented as Mean ± SEM, * = p < 0.05 compared to normal saline group - One way ANOVA followed by Dunnett's post hoc test of multiple comparison, n=6, NS - Normal Saline, MRE = Methanol Root Extract of *Ficus capensis*, SV = Sodium valproate.

Table 5: Effect WHF and SV on pentylenetetrazole induced seizure in mice

Treatment (mg/kg)	Mean onset of seizure (min)	Quantal protection	Protection against seizure (%)
NS	9.17±1.55	0/6	0.0
WHF 100	20.17±4.31*	2/6	33.3
WHF 200	23.33±2.78**	3/6	50.0
WHF 400	19.67±3.13*	2/6	33.3
SV 200	-	6/6	100.0

Protection against seizure and mortality expressed as percentages; Mean onset of seizures presented as Mean ± SEM, ** = p < 0.001 compared to normal saline group - One way ANOVA followed by Dunnett's post hoc test of multiple comparison, n=6, NS - Normal Saline, WHF = Hexane fraction of *Ficus capensis*, SV = Sodium valproate.

DISCUSSION

The preliminary phytochemical screening of the methanol root extract of *Ficus capensis* revealed the presence of saponins, tannins, glycosides, steroids, terpenoids, alkaloids and flavonoids while the hexane fraction contained steroids/terpenes and tannins. These phytochemical constituents have been reported to possess different kinds of pharmacological properties [35]. This include anti-oxidative [36], anti-cancer [37] and anti-malarial [38]. Triterpenes and steroids, among other phytochemicals have been reported to possess anticonvulsant activity [39].

Determination of median lethal dose value of plants used by traditional medicine

practitioners using acute toxicity study is of paramount importance because it provides information regarding the margin of safety of the plant. The i.p median lethal dose (LD₅₀) value of the methanol root extract was found to be greater than 1000 mg/kg body weight in Swiss albino mice. This LD₅₀ value implies that the methanol root extract is relatively safe [40]. Doses of less than or equal to 30% of the LD₅₀ which have been demonstrated to be relatively safe for ethno-pharmacological research were used throughout the research procedure [41].

The outcome of the study provides evidence that MRE possess significant anticonvulsant activity. The effectiveness of the plant extract in the experimental

convulsion paradigm used probably suggests that the herb could be used to manage epilepsy especially *petit mal* seizures and human generalized absence seizures.

MRE failed to alter MES thresholds at all doses tested in contrast to the positive control agent phenytoin. MEST is a standard AEDs test that evaluates the test material's ability to protect against hind limb tonic extension (HLTE) phase of the MEST [42]. It is a model for generalized tonic-clonic seizure, which is highly reproducible with consistent end-point [43].

MEST is used to validate pre-clinical test that predicts drug effectiveness in generalized seizures of the tonic-clonic (grand mal) type [44]. Drugs that act on sodium channels e.g. carbamazepine, phenytoin, oxcarbazepine and lamotrigine are known to suppress hind limb tonic extension induced by maximal electroshock [45] thus the study suggests that MRE does not interfere with the sodium channels to elicit its anticonvulsant effect.

The study revealed that MRE, WHF and valproic acid inhibited pentylenetetrazole (PTZ)-induced seizures. MRE and WHF dose independently suppressed the onset and latency of seizure induced by PTZ. The pentylenetetrazole (PTZ) test represents a valid model for human generalized and absence seizures [46]. Anticonvulsant activity in PTZ test identifies compounds that can raise the seizure threshold in the brain [47,48]. PTZ has been shown to interfere with GABA neurotransmitter and the GABA receptor complex [49].

Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility. The exact mechanism of the epileptogenic action of PTZ at the cellular neuronal level is still unclear but it has been generally reported to produce seizures by inhibiting gamma-amino butyric acid (GABA) neurotransmission [50].

Enhancement of GABAergic neurotransmission has been shown to inhibit or attenuate seizures while inhibition of GABAergic neurotransmission activity is known to promote and facilitate seizure. Anticonvulsant agents such as diazepam, valproic acid and phenobarbitone inhibit PTZ-induced seizure by enhancing the action of GABA-receptors thus facilitating the GABA-mediated opening of chloride channels [51, 52]. Postsynaptic GABA_A-receptors are multi-unit complexes with binding sites for the endogenous ligands such as GABA, benzodiazepines, barbiturates and other ligands with a central chloride ion channel [53]. Thus, the inhibition of PTZ-induced seizures by the MRE and WHF suggests that their effects may be by enhancing GABAergic neurotransmission although it is also possible that it could also be via depressing glutamate-mediated excitation [54].

Conclusion

The methanol root extract and water insoluble n-hexane fraction of *F. capensis* had demonstrated significant anticonvulsant activity with moderate toxicity validating the ethno-medicinal claim of the use of the plant in the management of epilepsy.

Acknowledgment

We wish to acknowledge the efforts of Mal. Umar Muhammad and Mal. Mu'azu Mahmud of the Animal House, Department of Pharmacology and Therapeutic, Ahmadu Bello University, Zaria, Nigeria.

REFERENCES

1. Mc Namara, O., J. (2006). Pharmacotherapy of the epilepsies In: *Goodman and Gilman's. The pharmacological basis of therapeutics* (11th edition). Laurence, L.B., Lazo, S.J. Parker, K.L. (Eds). McGraw-Hill Companies, USA, Pp: 501-545.

2. Blume, W.T., Luders, H.O., Mizrahi, E., Tassinari, C., Emde, B. W. and Engel, J. (2001). Descriptive terminology for Ictal Seminology: Report of the ILAE task force on classification and terminology. *Epilepsia*, 42(9): 1212-8.
3. Chawla, S., Aneja, S., Kashyap, R. and Mallika, V. (2002). Etiology and clinical predictors of intractable epilepsy. *Pediatric Neurology*, 27(3): 186-191.
4. Aguwa, C.N. and Ochei, U. (1998). Epilepsy In: *Therapeutic Basis of Clinical Pharmacy in Tropics* 2nd Ed Aguwa C. N., SNAAP Press, Enugu-Nigeria, Pp, 333-33
5. Michael-Titus, A., Revest, P. and Shortland, P. (2007). *The nervous system*. Churchill Livingstone. Pp: 123-144.
6. Nwachukwu, C. N., Umeh, C. N., and Kalu, I. (2010). Identification and traditional uses of some common medicinal plants in Ezinihite Mbaise L.G.A., of Imo state. Report and opinions press. Pp: 1-8.
7. Balandrin, N. F. Kinghorn, A. D. and Farnsworth, N. R. (1993). Human medicinal agents from plants. *ACS symposium series* 534: 2-12.
8. Echu, F.A., Hassan, H.S., Hanwa, U.A., Sani, Y. M., Atiku, I. and Abdullahi, M. (2015). Phytochemical and antimicrobial studies of the leaves extract of *Piliostigma thonningii* Lin (Fabaceae). *Biological and Environmental Sciences Journal for the Tropics*, 12: 733-736.
9. Hassan, H. S., Musa, A. M., Hassan, A. S., Aliyu, A. B. and Abdullahi, M. S. (2009a). Antimicrobial activity of saponins fraction of the rhizome of *Asparagus africanus* Lam. *Biotropic Research International Journal*, 1: 49-55.
10. Farnsworth, N. R. (1988). Screening plants for new medicines. In: *Biodiversity*. National Academy Press, University of Illinois Chicago. Pp-178-184.
11. Hassan, H. S., Sule, M. I., Usman, M. and Ibrahim A. (2009b). Preliminary Phytochemical and antimicrobial screening of the stem bark extracts of *Bauhinia rufescens* Lam. *Bayero Journal of Pure and Applied Sciences*, 2(2); 53-55.
12. Mann, J. (1976). *Secondary metabolism*. Oxford University Press, London. Pp, 154.
13. Edeoga, H.O., Okwu, D.E., Mbaebie, B.O. (1984). Phytochemical constituents of some Nigerian medicinal plants. *African Journal of Biotechnology*. 4(7): 685-688.
14. Arbonnier, M. (2004). *Trees, Shrubs and Lianas of West African Dry Zones*. Cidrad, Margraf Publishers. Pp, 250-251
15. Solomon-Wisdom, G. O., Shittu, G. A. and Agboola, Y. A. (2011). Antimicrobial and Phytochemical Screening of *Ficus sur* (Forssk). *New York Science Journal*, 4:15-18.
16. Burkill, H.M. (1985). The useful plants of west tropical Africa, Royal Botanic Garden, Kew, UK. 3: 422
17. Ayinde, B.A. and Owolabi, O.J. (2009). Effects of the aqueous extract of *Ficus capensis* Thunb. (Moraceae) leaf on the gastrointestinal motility, *Journal of Pharmacognosy and Phytotherapy*, 1: 031-035.
18. Adebayo-Tayo, B. C. and Odeniyi, A. O. (2012). Phytochemical Screening and Microbial Inhibitory Activities of *Ficus capensis*. *African Journal Biomedical Resource*, 15: 35- 40
19. Mohamed, Z. M., Salem, A. Z., Salem, L. M., Camach, O. and Hayssam, M., A. (2013). Antimicrobial activities and phytochemical composition of extracts of *Ficus* species. *African Journal of Microbiology Research*, 7: 4207- 4219
20. Oyeleke, S., B., Dauda, B., E, N. and Boye, O., A. (2008). Antibacterial activity of *Ficus capensis*. *African Journal of Biotechnology* 7: 1414-1417.
21. Njoku-Oji, N. N., Nwike, C. V., Dimkpa, U. Ifegwu, N. O. L., Anike, C., Maduka, S. O. Sobanke, O. A. and Uchefuna, R. C. (2016). Hematological Changes Following Oral Administration of Aqueous Leaf Extract of *Ficus capensis* in Albino Rats. *Science Domain International*, 5(1): 1-7.
22. Njoku-Oji, N. N., Osaji, D. E., Ifegwu, N. O., Uchefuna, R. C. and Ezejindu, D. N. (2015). Effects of aqueous extract of *Ficus capensis* leaf on some reproductive parameters in normal adult male Wister rats. *International Journal of Multidisciplinary Research and Development*, 2: 577-583.
23. Owolabi, O. J., Zuleikha, A., Nworgu, A., F., Buniyamin, A. A. and Charles, N. N. (2009). Evaluation of Tocolytic Activity of Ethanol Extract of the Stem Bark of *Ficus capensis* Thunb. (Moraceae). *Acta Poloniae Pharmaceutica- Drug Research*, 3:293-296.
24. Daiko, O. A., Tende, J. A., Okey, S. M., Eze, E. D. and Isa, A. S. (2012). The effect of aqueous extract of leaf *Ficus capensis* Thunb (Moraceae) on in-vivo Leukocyte Mobilization in Wister Rats. *British*

- Journal Pharmacology and Toxicology* 3(3): Pp, 110-114.
25. Owolabi, O. J. (2013). Active ileum relaxant fractions from the leaves of *Ficus capensis* Thunb (Moraceae). *Nigerian Journal of Pharmaceutical Sciences*, 12(1): 1-7.
 26. Ramde-Tiendrebeogo, A., Tibiril, A., Hilou, A., Lompo, M., Millogo-Kone, H., Nacoulma, O. G. and Guissou, I. P. (2012) antioxidative and antibacterial activities of phenolic compounds from *Ficus sur* Forssk. and *Ficus sycomorus* L (Moraceae): potential for sickle cell disease treatment in Burkina Faso, *International Journal of Biology and Chemistry Sciences*. 6: 328-336.
 27. Gelfand, M., Mavi, S., Drummond, R. B. and Ndemera, B. (1985). *The traditional medicinal practitioner in Zimbabwe*. Mambo press, Gweru, Zimbabwe, Pp, 411
 28. Umeokoli, B. O., Onyengbule, F. A., Gugu, T. H. and Igboeme, S. O. (2013). Evaluation of erythropoietic and anti-sickling properties of the *Ficus capensis* leaf extract in the treatment of anaemia. *Planta Medica* 79-PE29 doi: 10. 1055/s-0033-1352048.
 29. Sirisha, N., Sreenivasulu, M., Sangeeta, K. and Madhusudhana, C. C. (2010). Antioxidant Properties of Ficus Species. *International Journal of Pharm Tech Research*, 2: 2174-2182.
 30. Sander, J. W. (2004). The use antiepileptic drugs: Principles and practice. *Epilepsia*, 45 suppl. 6: 28-34.
 31. WHO Factsheets (2009). Available online at www.who.int/factsheets; accessed 10th December 2014.
 32. Banerjee, P. N., Filipi, D. and Allen-Hauser, W. (2009). The descriptive epidemiology of epilepsy, *Epilepsy Resource*, 85: 31-45.
 33. Lorke, D. (1983). A New Approach to Practical Acute Toxicity Testing. *Archives of Toxicology*. 54: 275-287.
 34. Swinyard, E. and Kupferberg, H. I. (1989). *Antiepileptic drugs: Detectio, quantification and Evaluation*, *Federation proceedings* 44: 39-43.
 35. Cowan, M.M. (1999). Plant Products as Antimicrobial Agents. *Clinical Microbiology Reviews*, 12 (14): 564-582.
 36. Okpuzor, J., Ogbunugafor, H.A., and Kareem, G.K. (2009). Antioxidative properties of ethyl acetate fraction of *Globimetula braunii* in normal albino rats. *Journal Biological Science*. 9; 470.
 37. Khwaja, T.A., Dias, C.B. and Pentecost, S. (1980). Recent studies on the anticancer activities of some of mistletoe and alkaloids. *Oncology*, 3: 1-10.
 38. Ichino, C., Kiyohara, H., Soonthornchareonnon, N., Chuakul, W., Ishiyama, A., Sekiguchi, H., Namatame, M., Otoguro, K., Omura, S., and Yamada, H. (2006). Antimalarial activity of biflavonoids from *Ochna integerrima*. *Planta Medica*, 72: 611-614.
 39. Musa, M.A., Musa, A.I., Kamal, M.J., and Magaji, M.G. (2014). Phytochemical Screening and anticonvulsant studies of ethyl acetate fraction of *Globimetula braunii* on laboratory animals. *Asian Pacific Journal of Tropical Biomedicine*, 4(4):285-289, doi:10.12980/APJTB.4.2014C925.
 40. Matsumura, F. (1985). *Toxicology of insecticides*. 2nd Ed., Plenum Press, New York. Pp. 588.
 41. Vongtau, H. O., Abbah, J., Mosugu, O., Chindo, B. A., Ngazal, I. E., Salawu, O. A., Kwanashie, H. O., and Gamaniel, K. S. (2004). Antinociceptive profile of the methanolic extract of *Neorautanania mitis* root in rats and mice. *Journal of Ethnopharmacology*, 92: 317-324.
 42. DeLorenzo, R. J., Raza, M., Saheen, F., Atta, U. R., Suria and Choudhary, M.I. (1992). Mechanisms of action of new antiepileptic drugs. *Advanced Neurology*, 76: 1-9.
 43. Stables, J. P., and Kupferberg, H.J. (1997). The NIH Anticonvulsant Drug Development Program: preclinical anticonvulsant screening project. In: Avanzini, G., Regesta, G., Tanganelli, P. and Avoli, M. (Eds). *Molecular and Cellular Targets for Antiepileptic Drugs*, John Libbey and Company Ltd., Pp. 191-198.
 44. Mares, P. and Kubova, H. (2006). Electrical stimulation induced model of seizures and epilepsy. Pitkanen, A., Schwarzkroin, P.A., Moshe, S.L. (Eds). Elsevier Academic Press, USA, 12:153-159.
 45. Rho, J.M. and Sanker, R. (1999). The pharmacological basis of antiepileptic drug action. *Epilepsia*, 40:1471-1483.
 46. Loscher, W. and Schmidt, D. (2006). New horizons in the development of antiepileptic drugs: Innovative strategies. *Epilepsy Research* 69:183-272.
 47. White, H.S., Wolf, H.H., Woodhead, J.H., and Kupferberg, H.J. (1998). The national institute of health anticonvulsant drug development program: screening for efficacy. In: French, J., Leppik I.E. and Ditcher M.A. (Eds). *Antiepileptic drug development: Advances in Neurology*, Vol. 76.

- Lippincott-Raven Publishers, Philadelphia. Pp. 29-39.
48. Raza, M., Shaheen, F., Choudhary, M.I., Suria, A., Atta ur Rahman, Sombati, S., and Delorenzo, R. J. (2001). Anticonvulsant activities of the FS-1 sub fraction isolated from roots of *Delphinium denudatum*. *Phytotherapy Research*, 15, 426-430.
 49. DeDeyn, P.P., D'Hoope, R., Marescau, B., and Pei, Y.Q. (1992). Chemical model for Epilepsy with some references to their applicability in the development of anticonvulsants. *Epilepsy Research*, 12: 87-110.
 50. De Sarro, G., Ferreri, G., and Gareri, P. (2003). Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents. *Pharmacology Biochemistry and Behaviors*, 74: 595-602.
 51. Olsen, R.W. (1981). GABA-Benzodiazepine-Barbiturate receptor interactions. *Journal of Neurochemistry*, 37: 1-13.
 52. Gale, M.K. (1992). GABA and epilepsy basic concepts from preclinical research. *Epilepsia*, 33, 33-512.
 53. Leeb-Lundberg, F., Snowmann, A., and Olsen, R. W. (1981). Interaction of anticonvulsants with the Barbiturate/Benzodiazepine/GABA receptor complex. *European Journal of Pharmacology*, 72: 125-129.
 54. Aragão, G.F., Carneiro, L.M.V., Junior, A.P.F., Bandeira, P.N., Lemos, I.L.G., Viana, G.S.d.B. (2009). Evidence for excitatory and inhibitory amino acids participation in the neuropharmacological activity of alpha- and beta amyrrin acetate. *The Open Pharmacological Journal*; 3:9-16.